Investor Presentaiton

Q3 & 9M FY23 Consolidated Profit & Loss Statement METROPOLIS The Pathology Specialist Profit & Loss Statement (Rs. Crs.) Q3FY23 Q3FY22 Y-o-Y 9MFY23 9MFY22 Y-o-Y Total Revenue from Operations 285.5 293.1 -2.6% 865.7 922.4 -6.2% EBIDTA (before CSR & ESOP) 77.2 80.5 -4.1% 231.9 279.3 -17.0% EBIDTA (before CSR & ESOP) Margin 27.1% 27.5% 26.8% 30.3% CSR & ESOP 4.5 4.3 4.2 9.5 Reported EBIDTA 72.7 76.2 -4.6% 223.6 269.8 -17.1% Reported EBIDTA Margin 25.5% 26.0% 25.8% 29.3% Depreciation 23.1 16.9 65.8 45.2 Other Income 6.8 2.6 14.0 11.9 EBIT 56.4 61.9 -8.9% 171.8 236.5 -27.4% Finance Cost 8.4 5.8 26.2 15.5 Exceptional Items (Gain / (Loss) 15.9 Profit Before Tax 48.0 56.1 -14.4% 145.6 236.9 -38.5% Taxes 12.1 14.9 35.7 62.3 Profit After Tax PAT Margin 35.9 41.2 -12.9% 109.9 174.5 -37.0% 12.6% 14.1% 12.7% 18.9% 22 22

View entire presentation